VALIDOGEN GmbH (vormals/formerly VTU Technology)

VALIDOGEN ist ein fuhrendes Forschungs- und Entwicklungsunternehmen fur die Proteinproduktion mit der Hefe Pichia pastoris. VALIDOGEN bietet Hochleistungstechnologien zur Entwicklung wirtschaftlich attraktiver Produktionsprozesse beispielsweise zur Herstellung von Biopharmazeutika und Enzymen. VALIDOGEN wird ein privates Unternehmen im Besitz der KonValue Gruppe.

Weitere Informationen:,

VALIDOGEN, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production known as UNLOCK PICHIA. VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailormade solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries. VALIDOGEN will be a private company and independent subsidiary of KonValue Group.

More Information:,

  • Mitarbeiterzahl

  • Ausrichtungen
    • Auftragsforschung
    • Lohnhersteller / Produzenten
  • Gegründet

  • Aktualisiert am


Join us at BIO International Convention 2014

VTU Technology will be exhibiting at the BIO 2014 International Convention, June 23-26, San Diego, CA. We will be happy to provide you more information on our outstanding Pichia pastoris protein expression platform & services and we are looking forward to giving you insights into our latest technology developments. Please feel free to contact us directly or via the event´s partnering system for the arrangement of a meeting or just see us at our booth at the Austrian Pavilion, 4407. Cutting-edge, exclusive, proprietary technologies and know-how are the basis for the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities ever reported. We guarantee tight development timelines and deliver production processes being economically viable robust and readily scalable safe - no risk of viral or endotoxin contamination accompanied by simplified protein purification procedures Services from VTU Technology High speed expression strain development Upstream process development and optimization Downstream and analytical process development Small-scale production of purified non-GMP material Sound technology & data transfer to our customers Outlicensing opportunities fo - Human serum albumin (HSA) - Human serum transferrin (HST) - HSA-fusion proteins - Cell culture proteins

From Consulting Engineers to Technology Company

With more than 300 employees and 15 sites, VTU is now competing in the premier league of technology service providers. The VTU Group - planners, consultants and suppliers of high-tech process plants for industry - will have more than 300 employees as of July 2013, which means that a small company of process engineering consultants, established by Dr. Michael Koncar in 1990, has developed into a European technology company. VTU takes care of a large number of substantial customers, including major international pharmaceutical and chemical companies, at 15 current sites in Austria, Germany, Italy, Switzerland and Romania. VTU is now putting the expertise gathered in the company’s early stages from the planning of pharmaceutical and biodiesel plants into practice internationally as an engineering specialist and technology service provider for the pharmaceutical and biotechnology, chemical and metallurgy, crude oil and natural gas industries with the addition of the power engineering sector. “We have always relied on highly qualified and highly-motivated staff in all our activities. We have also always endeavoured at all times to offer the team a corporate environment where delivering peak performances is fun even when times are hard.” Quote by Dr. Michael Koncar, company founder and Holding MD VTU is banking on further steady growth based on long-term collaborative customer relationships. Increases to date have been in the form of organic growth generated from the company’s own efforts. The management is characterised by employees who have worked at VTU for many years and who are responsible for the company’s strategic alignment. Sustainable business management takes precedence over profit maximisation and the company has worked very successfully for many years by taking this fundamental approach.

VTU´s Pichia pastoris protein expression platform

By applying VTU´s Pichia pastoris protein expression technology researchers at VTU have repeatedly demonstrated their ability to rapidly produce a wide range of different proteins (serum proteins, cytokines, Fabs and other antibody derived fragments, scaffold proteins, HSA-fusion proteins, Fc-fusion proteins and enzymes) by full exploitation of VTU´s protein expression technologies and optimized procedures for high-throughput expression strain development. VTU´s expression technology platform is based on the following technological advances: 1. Proprietary technology - VTU´s exclusive AOX1 promoter libraries provide an unprecedented genetic diversity with superior regulatory properties for fine tuning of gene expression by selecting the perfect match of promoter/target combinations. 2. FTO tools - VTU´s in-house modular plasmid system and platform strains enable the optimization of protein production and provide more flexibility to fulfill the different requirements of various expression tasks. 3. Optimized procedures - VTU´s team applies highly elaborated and time-saving procedures, based on a pool approach for transformation and a high-throughput cultivation - & screening regime allowing for maximization of output. Key components of VTU´s Pichia pastoris protein expression platform

VTU Technology to Showcase at Pichia 2014

VTU Technology, a leading expert in the field of Pichia pastoris protein expression and one of the main sponsors of the upcoming Pichia 2014 event (March 2-5, San Diego, CA USA), will be presenting its latest findings and exciting technology developments. To date, VTU has established a broad range of technologies and know-how for the fast-track generation of high performance Pichia protein production strains and processes. Exclusive proprietary technologies and profound experience of the VTU team lead to competitive production processes for a wide range of recombinant proteins. Don´t miss the opportunity to attend the following talks providing insights into the most versatile and powerful Pichia pastoris protein expression platform: Monday, March 3rd, 2014, 4:00 p.m.: Dr. Iskandar Dib, Principal Scientist Process Development & Analytics Short Lecture 15: Targeted process optimization and scale up to industrial scale with 2nd generation AOX1 promoter variants Tuesday, March 4th, 2014, 2.00 p.m.: Dr. Roland Weis, Head of Operations Short Lecture 25: Uniform GlcNAc2Man5-decorated proteins by Pichia pastoris: achievements in high-level production and characterization Tuesday, March 4th, 2014, 3.30 p.m.: Dr. Aid Atlic, Research Scientist Development & Fermentation Short lecture 29: Half-life extension of a chemokine by fusion to HSA: implications on producibility and in vitro / in vivo characteristics of the fusion protein Find more details in the attached Document.

Kongresse und Messen 2014

Kongresse und Messen 2014 Pichia 2014, 2-5 March, San Diego, California, USA 7th Annual Proteins & Antibodies Congress 2014, 3-4 April, London, UK BIO International Convention 2014, 23-26 June, San Diego, California, USA 7th international Congress on Biocatalysis - biocat 2014, Hamburg, 31 August – 4 September, Germany CPhI Worldwide 2014, 7-9 October, Paris, France Bio Europe 2014, 3-5 November, Frankfurt, Germany

PEPTALK, January 13-17, 2014, Palm Springs, USA

VTU Technology will be attending PEPTALK 2014, Palm Springs, California and will be available to provide more information on its oustanding Pichia pastoris protein expression platform & services and latest technology developments. Listen to VTU´s Head of Operations, Dr. Roland Weis speaking about "Uniform GlcNAc2Man5-Decorated Proteins by Pichia pastoris: Achievements in High-Level Production and Characterization"; January 13, 12.15 p.m, Pipeline 5 Engineering Genes, Vectors, Constructs and Clones Abstract: Heterogeneous N-linked glycan profiles on therapeutic proteins represent a regulatory disadvantage paired with an elevated workload to identify the respective glycan distribution from batch to batch. Next to its extraordinary secretion capacity, the established recombinant production host Pichia pastoris now features homogeneous N-glycan structures (GlcNAc2Man5) for reliable high-level production of demanding proteins. Case studies of the biological implications of these glycans on human serum proteins will be presented. Please feel free to contact us directly for the arrangement of a meeting.